Previous studies have suggested that USP14 is a potential target for anti-tumor therapies as shown in cancer cell models of multiple myeloma, lymphomas, breast, lung, liver, and colon cancer (Wang et al., 2016; Abramson, 2018; Jiang et al., 2019; Ma et al., 2020). Here, USP14 is linked to plasma cell myeloma.